Idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.But a new drug made by Seattle-based Gilead Sciences Inc. appears to offer hope for fighting the disease, according to a study published online in the New England Journal of Medicine in advance of its March 13 print issue.

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/KxhinekgOq8/271631.php

rehab sport